title: [Our experiences of preoperative chemo-radiotherapy for T4 primary rectal cancer].
abstract: We reviewed 7 cases of clinical record with preoperative chemo-radiotherapy to evaluate the clinical effectiveness of the chemo-radiotherapy for T4 rectal cancer. The preoperative radiation therapy consisted of 40-45 Gy delivered in fractions of 1.8-2.0 Gy per day, five days a week. A treatment of 5-fluorouracil, 500 mg/body per day intravenously, or oral UFT-E (300 mg/m2) with l-leucovorin (75 mg) per day, or oral S-1 (80 mg/m2) per day five days a week, was given during radiotherapy. Grade 1 or 2 adverse effects occurred in 3 patients during chemo-radiotherapy, but the completion of chemo-radiotherapy was achieved in all of the 7 patients. Tumor invasion identified by CT and MRI to other organs in the pelvis disappeared in four cases with complete or partial response after a month of chemo-radiotherapy. Although the other organs were also removed during surgery in 4 patients, curative surgery was performed in 5 patients. There was no histological invasion seen to other organs in 4 patients, and one patient had histological complete disappearance of tumor. Although complications after surgery were found in all of the patients, they were improved by conservative treatment. One of 4 patients with curative surgery had liver and local recurrence, but others survived without recurrence. Preoperative chemo-radiotherapy was expected to be a safe and effective treatment to improve the resection rate and prognosis for T4 rectal cancer.
authors.affiliation: Dept. of Surgery, Fujita Health University.
authors.forename: Harunobu
authors.initials: H
authors.lastname: Sato
authors.forename: Koutarou
authors.initials: K
authors.lastname: Maeda
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Hanai
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Koide
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Aoyama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsuoka
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Katsuno
authors.forename: Masuo
authors.initials: M
authors.lastname: Funahashi
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Agata
authors.forename: Tomohito
authors.initials: T
authors.lastname: Noro
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Honda
authors.forename: Miho
authors.initials: M
authors.lastname: Shiota
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D005472:Fluorouracil